TRXPF Quote, Financials, Valuation and Earnings

PeptiDream has a net margin of 9.47% compared to Torii Pharmaceutical's net margin of -24.41%. Torii Pharmaceutical's return on equity of 4.45% beat PeptiDream's return on equity of 34.1%.

Torii Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Torii Pharmaceutical has higher upside potential than PeptiDream, analysts believe Torii Pharmaceutical is more attractive than PeptiDream.

Torii Pharmaceutical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

Torii Pharmaceutical has a quarterly dividend of $0.38 per share corresponding to a yield of 3.07%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Torii Pharmaceutical pays 72.47% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Torii Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Torii Pharmaceutical quarterly revenues are $96.3M, which are larger than PeptiDream quarterly revenues of $27.8M. Torii Pharmaceutical's net income of $9.1M is higher than PeptiDream's net income of -$6.8M. Notably, Torii Pharmaceutical's price-to-earnings ratio is 19.44x while PeptiDream's PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Torii Pharmaceutical is 1.78x versus 4.76x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Shionogi & has a net margin of 9.47% compared to Torii Pharmaceutical's net margin of 42.36%. Torii Pharmaceutical's return on equity of 4.45% beat Shionogi &'s return on equity of 12.6%.

Torii Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Shionogi & has an analysts' consensus of -- which suggests that it could fall by --. Given that Torii Pharmaceutical has higher upside potential than Shionogi &, analysts believe Torii Pharmaceutical is more attractive than Shionogi &.

Torii Pharmaceutical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Shionogi & has a beta of 0.238, suggesting its less volatile than the S&P 500 by 76.209%.

Torii Pharmaceutical has a quarterly dividend of $0.38 per share corresponding to a yield of 3.07%. Shionogi & offers a yield of 2.37% to investors and pays a quarterly dividend of $0.11 per share. Torii Pharmaceutical pays 72.47% of its earnings as a dividend. Shionogi & pays out 28.57% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Torii Pharmaceutical quarterly revenues are $96.3M, which are smaller than Shionogi & quarterly revenues of $784.3M. Torii Pharmaceutical's net income of $9.1M is lower than Shionogi &'s net income of $332.2M. Notably, Torii Pharmaceutical's price-to-earnings ratio is 19.44x while Shionogi &'s PE ratio is 19.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Torii Pharmaceutical is 1.78x versus 10.22x for Shionogi &. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 9.47% compared to Torii Pharmaceutical's net margin of -11.44%. Torii Pharmaceutical's return on equity of 4.45% beat Nxera Pharma's return on equity of -8.65%.

Torii Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Torii Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Torii Pharmaceutical is more attractive than Nxera Pharma.

Torii Pharmaceutical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

Torii Pharmaceutical has a quarterly dividend of $0.38 per share corresponding to a yield of 3.07%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Torii Pharmaceutical pays 72.47% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Torii Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Torii Pharmaceutical quarterly revenues are $96.3M, which are larger than Nxera Pharma quarterly revenues of $43.6M. Torii Pharmaceutical's net income of $9.1M is higher than Nxera Pharma's net income of -$5M. Notably, Torii Pharmaceutical's price-to-earnings ratio is 19.44x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Torii Pharmaceutical is 1.78x versus 2.91x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 9.47% compared to Torii Pharmaceutical's net margin of -9.79%. Torii Pharmaceutical's return on equity of 4.45% beat Takeda Pharmaceutical's return on equity of 1.49%.

Torii Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.15 which suggests that it could grow by 14.63%. Given that Takeda Pharmaceutical has higher upside potential than Torii Pharmaceutical, analysts believe Takeda Pharmaceutical is more attractive than Torii Pharmaceutical.

Torii Pharmaceutical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.347%.

Torii Pharmaceutical has a quarterly dividend of $0.38 per share corresponding to a yield of 3.07%. Takeda Pharmaceutical offers a yield of 4.1% to investors and pays a quarterly dividend of $0.33 per share. Torii Pharmaceutical pays 72.47% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Torii Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Torii Pharmaceutical quarterly revenues are $96.3M, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Torii Pharmaceutical's net income of $9.1M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Torii Pharmaceutical's price-to-earnings ratio is 19.44x while Takeda Pharmaceutical's PE ratio is 69.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Torii Pharmaceutical is 1.78x versus 1.61x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.